Latest Conference Articles

June 27th 2022, 1:00pm

Educated Patient® Metastatic Breast Cancer Summit: June 11, 2022

Watch Dr. Suchita Pakkala, Dr. Jane Meisel, Dr. Keerthi Gogineni and Kelly Shanahan discuss updates in disease management during the CURE Educated Patient Metastatic Breast Cancer Summit.

June 24th 2022, 1:00pm

Educated Patient® Metastatic Breast Cancer Summit: June 11, 2022

Watch Dr. Suchita Pakkala, from Emory University School of Medicine, discuss estrogen receptor-positive disease, during the CURE Educated Patient Metastatic Breast Cancer Summit.

June 17th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Jeremie Calais, Dr. Tian Zhang, Dr. Landon C. Brown and Jim Rosenfield answer questions about novel agents and strategies during the CURE Educated Patient Prostate Cancer Summit.

June 16th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Landon C. Brown, from Atrium Health Levine Cancer Institute, discuss approaches to hormone therapy, during the CURE Educated Patient Prostate Cancer Summit.

June 15th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Tian Zhang, from UT Southwestern Medical Center, discuss novel agents, during the CURE Educated Patient Prostate Cancer Summit.

June 14th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Jeremie Calais, from UCLA, discuss novel imaging strategies, during the CURE Educated Patient Prostate Cancer Summit.

June 13th 2022, 9:00pm

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

June 13th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Veda N. Giri, Dr. Umang Swami and Sue Friedman answer questions about genetics and genomics during the CURE Educated Patient Prostate Cancer Summit.

June 12th 2022, 2:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Umang Swami, from Huntsman Cancer Institute, discuss genomic changes and PARP inhibitors, during the CURE Educated Patient Prostate Cancer Summit.

June 11th 2022, 2:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.

June 10th 2022, 9:00pm

ASCO Annual Meeting

Brukinsa, which was approved in September 2021, resulted in better oucomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

June 10th 2022, 7:00pm

ASCO Annual Meeting

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

June 10th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

June 9th 2022, 7:00pm

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

June 9th 2022, 3:00pm

ASCO Annual Meeting

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.

June 9th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

June 8th 2022, 9:00pm

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

June 8th 2022, 7:00pm

ASCO Annual Meeting

One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.

June 8th 2022, 3:00pm

ASCO Annual Meeting

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

June 8th 2022, 1:00pm

Educated Patient® Prostate Cancer Summit: May 21, 2022

Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

June 7th 2022, 9:00pm

The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.

June 7th 2022, 3:00pm

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

June 6th 2022, 9:00pm

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

June 6th 2022, 7:00pm

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

June 6th 2022, 3:00pm

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

June 6th 2022, 1:00pm

ASCO Annual Meeting

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

June 5th 2022, 10:00pm

ASCO Annual Meeting

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

June 5th 2022, 5:15pm

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

June 5th 2022, 1:00pm

ASCO Annual Meeting

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

June 4th 2022, 11:50pm

ASCO Annual Meeting

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.